Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 19 February 2025, 14:42 HKT/SGT
Share:
Goldman Sachs Raises Everest Medicines' Target Price to HK$48.32 on Stronger Commercial and R&D Outlook

HONG KONG, Feb 19, 2025 - (ACN Newswire) - Goldman Sachs’ latest report on China’s biotechnology sector highlights Everest Medicines (1952.HK) as a company on track to achieve EBITDA break-even by the end of 2025. This outlook is driven by the accelerated commercialization of Nefecon®, which was recently included in China’s National Reimbursement Drug List (NRDL). The report underscores that expanded reimbursement coverage is expected to significantly boost market potential in treating IgA Nephropathy (IgAN) and address a substantial unmet medical need. Goldman Sachs notes, “Everest targeted EBITDA break-even by YE25, expecting the NRDL coverage to unleash the significant patient need in IgAN.”

Beyond Nefecon®, Everest’s BTK inhibitor EVER001 is emerging as a promising pipeline asset, with encouraging early clinical data in primary membranous nephropathy (pMN). According to Everest’s Phase 1b/2a trial results, EVER001 demonstrated quick disease remission in pMN patients, with 82% of low-dose and 86% of high-dose patients achieving clinical remission based on 24-hour proteinuria reduction, and 91% and 100% achieving immunological complete remission, respectively, based on anti-PLA2R autoantibody decrease. The data also showed clear dose-dependency across key biomarkers, reinforcing the drug’s mechanism of action. With no major safety concerns reported, EVER001 has the potential to be a best-in-class therapy for pMN.

Goldman Sachs also highlights EVER001’s global development potential, as Everest prepares for multinational clinical trials to evaluate its benefits across different ethnic populations. The report notes that while pMN is a smaller market than IgAN, it shares strong synergies in disease mechanism and treatment approaches, making it a strategically valuable addition to Everest’s renal disease franchise.

The report further emphasizes China’s evolving biotech landscape, where global licensing and partnerships are becoming key drivers of growth. Everest’s consistent execution of its renal and mRNA-focused strategy, combined with its emphasis on global expansion, positions the company well for sustained success.

Reflecting these positive developments, Goldman Sachs has raised its 12-month target price for Everest Medicines to HK$48.32, nearly doubling from the previous HK$24.50. The upgrade factors in stronger commercial visibility, EVER001’s potential in pMN, and an improved financial outlook as Everest advances toward profitability.




Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Hola Prime Launches Performance Coaching Initiative to Tackle the #1 Barrier to Trader Success: The Mind  
May 30, 2025 19:00 HKT/SGT
Mitsubishi Corporation Establishes New Corporate Venture Capital Company  
Friday, May 30, 2025 5:36:00 PM
The PropertyGuru Asia Property Awards (Middle East) return for 2025 edition with inaugural Dubai launch  
May 30, 2025 14:00 HKT/SGT
Honda to Co-develop Refueling Port Connecting System for On-orbit Satellite Refueling with Astroscale  
Friday, May 30, 2025 10:54:00 AM
IFS and NEC Strengthen their Strategic Partnership to Create New Value  
Friday, May 30, 2025 9:11:00 AM
Genetec maintains profitability in Q3FY2025 on higher revenue  
May 29, 2025 20:00 HKT/SGT
Naoris Protocol Raises $3M in Strategic Round Led by Mason Labs  
May 29, 2025 19:00 HKT/SGT
MODONG Coffee Proudly Sponsors "G-DRAGON 2025 WORLD TOUR [Ubermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP" as Official Sponsor  
May 29, 2025 18:19 HKT/SGT
Mazda Production and Sales Results for April 2025  
Thursday, May 29, 2025 5:44:00 PM
Euro Manganese Closes C$11.2 million (A$12.3 million) Financing  
May 29, 2025 16:09 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: